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The CYP2A6 gene, which codes the CYP2A6 enzyme, has known to have ahigh polymorphism. 
This polymorphism could decrease, increase, or eliminate the CYP2A6 enzyme activity. CYP2A6*4, an 
inactive allele, decreased the CYP2A6 enzyme activity. One of the CYP2A6 enzyme-specific substrates 
is nicotine. This inactive allele could decrease nicotine metabolism that causes high nicotine levels in 
the blood. In addition, it caused the increasing levels of Low-Density Lipoprotein Cholesterol (LDL-
C) by expanding the lipolysis process. The purpose of this research was to evaluate the effect of the 
CYP2A6*4 allele gene on LDL-C levels. Respondents in this study were 31 male Javanese smokers. 
This research is an analytic observational study with a cross-sectional design. Polymerase chain 
reaction (PCR) methods use to identification the CYP2A6*4 allele gene. This study shows that a high-
frequency CYP2A6*4 alleles gene among the subject was detected, with an allele frequency is 93.55%. 
Furthermore, this CYP2A6*4 allele gene did not impact LDL-C levels, with the Odd Ratio value was 
1.636 (P-Value = 0.737). In conclusion, the CYP2A6*4 allele gene does not significantly affect the 
LDL-C levels in Javanese Indonesian smokers.  
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According to the (World Health Organization, 2020), more than 1.3 billion people worldwide 
consume cigarettes. In addition, the death rate from smoking reaches more than 8 million people each 
year which is more than 7 million people are active smokers and 1.2 million people are passive 
smokers. The Indonesia Ministry of Health (2018) has reported that Indonesia is the third country with 
the highest cigarette consumers in the world. The prevalence of heavy smokers in this country was 
24.3%, and light smokers were 5%, while the percentage of smokers aged ≥ 15 years in males was 
62.9% and in females was 4.8% (Kemenkes RI, 2018). The Tobacco Atlas in Indonesia (2020) has 
reported that every year diseases caused by tobacco killed more than 225 thousand Indonesian people. 
Still, more than 500 thousand children (10-14 years old) and 6,4 million adults (≥ 15 years old) 
continuing to consume tobacco every day. 
Cigarette smoke consists of various toxicologically compound, including nicotine, carbon 
monoxide (CO), polycyclic aromatic hydrocarbons (benzopyrene), tobacco-specific nitrosamines, 
aldehydes (acrolein, formaldehyde), hydrogen cyanide, nitrogen oxides, benzene, toluene, phenols 
(phenol, cresol), and some of the inorganic compounds (arsenic, nickel, chromium, cadmium) 
(Alessandro et al., 2011; Breitling, 2013). The active compound in cigarette smoke is nicotine. It is 
inhaled not only by active smokers but also by secondhand smokers (Benowitz, 2011; Mishra et al., 
2015). Nicotine contributes to influencing Low-Density Lipoprotein Cholesterol (LDL-C) levels by 
increasing lipolysis. High levels of nicotine in the blood will stimulate the sympathetic adrenal system 
and increase catecholamine secretion. It will expand lipolysis of fat tissue adipose and increasing free 
fatty acids. Furthermore, free fatty acids will esterify as triacylglycerols and esters cholesterol in the 
liver. They are secreted into the bloodstream as VLDL and will convert into LDL as the final product 
(Devaranavadgi et al., 2012; Sanhia et al., 2015). This compound was metabolized through the 
CYP2A6 enzyme, which coded by the CYP2A6 gene.  This gene has a highly polymorphic form that 
could decrease, eliminate, or increase the CYP2A6 activity enzyme (Di et al., 2010). 
The active CYP2A6 allele gene is CYP2A6*1 (wild type), while one of the inactive alleles is 
CYP2A6*4, a deletion allele.  Combining the CYP2A6*4 allele gene with other allele genes results in 
decreased nicotine metabolizing enzyme activity, impacting nicotine levels in the blood and affecting 
LDL-C levels (Patramurti and Fenty, 2019; Tanner, A et al., 2017; Yusof and Gan, 2009). In our 
previous study has revealed a high frequency of these inactive alleles among the Javanese Indonesian 
population and identified them as slow metabolizers (Patramurti et al.,2017). Therefore, in this study, 
we learned the CYP2A6*4 allele gene frequencies among the Javanese Indonesian smokers to explain 
the CYP2A6*4 allele genes effect on LDL-C levels as a possible risk factor in developing 
cardiovascular diseases. 
 
MATERIALS AND METHOD  
Materials 
Whole blood; Forward primer for CYP2A6*1 and CYP2A6*4 alleles: (5 'CCT CAT CAC ACA 
CAA CTT CCT C 3'); reverse primer for CYP2A6*1 alleles: (5 'CGC AGG TAC TGG GTG CTT 
GGT AG 3'); reverse primer for the CYP2A6*4 allele: (5 'TGC AGG TAC TGG GTG CTT GGT AG 
3'); Promega Taq Green Master Mix; FavorPrepTM Genomic DNA Mini Kit (DNA isolation kit); 10X 
Tris Borate EDTA (TBE) Buffer pH 8.3 (Omnipur); agarose (Genedirex); Loading Dye (SMOBiO); 
GelRed
TM
 Nucleic Acid Gel Stain (SMOBiO); and AccuBand
TM
 100 bp+3K DNA ladder II 




The sample population involved 31 adult subjects from online driver motorcycles. The 
respondent recruitment process is using a broadcast system on the social media group. According to 
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this study's inclusion and exclusion criteria, the researcher selected the respondents who register. The 
inclusion criteria are male active smokers with health conditions and had three generations of Javanese 
tribe, namely parents, grandparents, and great grandparents. For at least 20 years, the participant will 
be active smokers with cigarettes per day of ≥10 and willing to fill out informed consent. The 
exclusion criteria are patients taking regular medication or treatment for smoking cessation and an 
illness condition required rest of ≥10 days in the past month. In addition, patients with cardiovascular 
disease. 
A standard questionnaire was used to obtain demographics data, smoking behavior, and medical 
history from each respondent. The questionnaire is only filled out by respondents eligible to participate 
in this study and voluntarily participate in the research. All information relating to the respondent's 
identity will be kept confidential. Therefore, the data collected from the respondent have managed 
anonymously and be known only to the researcher. The procedure utilized in this study was authorized 
by the Health Research Ethics Committees, Faculty of Medicine, Duta Wacana University, 
Yogyakarta, with ethical clearance. No. 1235/C.l6/FK/202l. 
 
Cigarette dependence analysis   
The cigarette dependence was analyzed using the Fagerstrom Test for Nicotine Dependence 
(FTND) instrument. This instrument's overall total score is 0-10, with a higher FTND score indicating 
a stronger dependence on nicotine (Heatherton et al., 1991).  
 
Blood sampling 
Respondent first examined the general condition, which measured BMI and blood pressure.  
The blood sample was taken as much as 3 mL from a vein with the patient fasting for 12 hours and 
collected into a K2 vacutainer tube containing EDTA (1.8 mg/mL blood). The blood is stored at ± 4
o
C. 
The Low-Density Lipoprotein Cholesterol (LDL-C) was promptly measured using the Direct CHOD 
PAP method in a clinical laboratory. 
 
DNA isolation 
DNA isolation aims to obtain pure DNA and separate it from other components such as fat, 
carbohydrates, and protein (Murtiyaningsih, 2017). In this study, DNA isolation used the whole blood 
sample because blood cells contain more DNA than other samples (Pelt-Verkuil et al., 2008). The 
DNA isolation in this study was carried out using the FavorPrep
TM
 Genomic DNA Mini Kit. The 
procedure was carried out following the stated protocol with a blood sample of 200 µL. The DNA 
isolate purity test was carried out by electrophoresis method using 1.0% agarose gel. For about 3.0 µL 
of DNA, the isolate was mixed with 2.0 µL of aquabidestilata, and 1.0 µL of loading dye. 5 µL of this 
mixture was injected into the agarose well gel. Electrophoresis was running at 110 V for 30 minutes. 
The DNA isolates were stored at temperature -70
o
C and stable for two years. 
 
Identification of CYP2A6*1 and *4  
The CYP2A6*1 and *4 alleles gene in isolated DNA were analyzed using the PCR method. 
CYP2A6*4 alleles gene has a whole gene deletion due to unequal crossover junctions (Fukami et al., 
2007). A specific primer used for CYP2A6*1 and *4 alleles gene identification using the PCR method. 
The primer using in this study would amplify the nucleotide sequence of the gene from 10643 to 
10993. There are six variations in the nucleotide sequence between the CYP2A6*1 and CYP2A6*4 
genes among this amplified sequence. The primers forward (5'-CCT CAT CAC ACA CAA CTT CCT 
C-3') used in this study will anneal to both CYP2A6*1 and CYP2A6*4 alleles. We used two types of 
reverse primers for the CYP2A6*1 and CYP2A6*4 alleles are 5'-CGC AGG TAC TGG GTG CTT 
GGT AG-3' and 5'-TGC AGG TAC TGG GTG CTT GGT AG-3'. These primers will produce a PCR 
product with a length size of 350 bp. As the two primer reverse has a one difference nucleotide base 
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located on the first sequence (C>T), each reverse primer will anneal to a specific allele. In addition, we 
also adopted the PCR conditions using by Gitaningtyas (2018).  
The PCR reaction consists of 12.50 μL Taq Green Master Mix Promega, 1.25 μL forward 
primer, 1.25 μL reverse primer, 5.0 μL DNA isolate, and 5.0 μL free water nuclease with a final 
mixture volume of 25.0 μL. The PCR was performed under the following conditions: initial 
denaturation at 95°C for 5 minutes; followed by denaturation at 98°C for 20 seconds; annealing at 
64°C for 15 seconds and extension at 72°C for 30 seconds. The amplification cycle was carried out 30 
times and then ended with a final extension at 72°C for 5 minutes. 
 
PCR product analysis  
The PCR products were analyzed using the electrophoresis method using 1.5% agarose. Each 
well was consisting 5 µL of PCR products. Electrophoresis was carried out with a voltage condition of 
110V and running for 30 minutes. The results obtained were viewed using a UV transilluminator and 
documented using a DSLR camera. The CYP2A6*1 and CYP2A6*4 allele PCR products detected on 
the electrophoresis method have the same band length of 350 bp. 
 
Data Analysis 
The CYP2A6*1 and CYP2A6*4 allele was analyzed using the PCR product detected on the 
electrophoresis method with a band length of 350 bp. The allele frequencies were calculated using the 
equation (1) (2). In addition, the Odds Ratio (OR) value was calculated with SPSS software version 
25.0 using Mantel-Haenszel Common Odds Ratio Estimate (95% CI) to describe the effect of the 





RESULT AND DISCUSSION 
Participants in this study were 31 male active smokers with health conditions and had three 
generations of Javanese tribe, namely parents, grandparents, and great grandparents. The participant 
for at least 20 years to be active smokers with cigarettes per day of ≥10. In this study, the 
characteristics and health observation data of respondents as shown in Table 1. 
 
Table 1. Characteristics and health observation data of respondents 
Respondents Characteristics Profile 
Characteristics n Mean ± SD Range 
Age (Years) 31 39.7±7.7 27-62 
First smoking (years) 31 15.7±4.2 7-30 
Cigarettes per day (Sticks) 31 13.5±4.4 10-21 
Smoking duration (Years) 31 23.2±4.8 20-38 
Respondents Health Observation 
Characteristics n Mean ± SD Range 
BMI 31 25.1±4.8 17-36 
     
Waist circumference (Cm) 31 89.5±11.3 65-112 
Systolic blood pressure (mmHg) 31 128.4 
±24.1 
90-195 
Diastolic blood pressure (mmHg) 31 82.6±9.4 65-100 
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As described in Table 1, all respondents in this study were adults with the age range of 27-62 
years old. Most of them worked as online motorcycle taxis. All of the respondents have smoked for 
more than 20 years. As shown in Table 1, some respondents have smoked before 15 years. The Health 
Ministry of Indonesia has reported that more than 30% of Indonesian children have smoked a cigarette 
before the age of 10 years (Kemenkes RI, 2018). They are some factors that encourages the children to 
smoke including TV advertisements, smoking environment, and sponsorships on activities in which 
teenagers are involved the most. In addition, based on cigarettes consume per day and the duration of 
smoking, this study indicated that the respondents are in the moderate-heavy category (Patramurti and 
Fenty, 2019; Watanabe et al., 2011). 
We have also done the health observations among the participants as described in Table 1. 
Based on BMI data and waist circumference, all of the respondents are in the overweight category. 
This condition is related to their job as online driver motorcycle, including the low level of physical 
activity category because most of the activities carried out on a seated vehicle. In addition, the systolic 
and diastolic blood pressure all of the respondents are at normal blood pressure (Perhimpunan Dokter 
Hipertensi Indonesia, 2019).   
The PCR products were identified by the electrophoresis method using 1,5% agarose gel.  
Figures 1 describe the CYP2A6*1 and the CYP2A6*4 PCR product. As shown in these figures, the 
specific primers used in this study would produce the PCR product with the same size (350bp). It is 
due to the only one nucleotide difference base using to amplify at the reverse primer. 
 
  
Figure 1. Electropherogram PCR products with CYP2A6*1 and*4 allele-specific primers 
 
M    : 100 bp + 3K bp DNA ladder  
S1-5 and 7 (Primer CYP2A6*1) : CYP2A6*1 allele PCR products (Normal allele) 
S1- 6 (Primer CYP2A6*4)  : CYP2A6*4 allele PCR products (Inactive allele) 
Electrophoretic conditions : 1.5% agarose stationary phase; mobile phase TBE 1X solution; 110V 
voltage with running time 30 minutes; injection volume 5 µL 
 
We have amplified all the DNA isolated samples. Based on our result in Table 2, both 
CYP2A6*1 and CYP2A6*4 alleles have the same allele frequencies, with a value are 93,55%. These 
results were in line with another study, in which CYP2A6*4 alleles were found a high frequency in the 
Javanese Indonesian population (Patramurti et al., 2017). In this study, we have also identified the 
genotype belonging to the respondent base on their allele. They are CYP2A6*1/*1 (normal 
metabolizer) 6.45%; CYP2A6*1/*4 (slow metabolizer) 87.10%; and CYP2A6*4/*4 (poor metabolizer) 
6.45%. This result was in line with the previous study, which is among the Javanese Indonesia 
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Genotype (Phenotype) Frequency 
CYP2A6*1/ CYP2A6*1 (normal 
metabolizer) 
6,45% 
CYP2A6*1/ CYP2A6*4 (slow 
metabolizer) 
87,10% 




The presence of the CYP2A6*4 allele significantly affects cigarette dependence. Individuals 
with the CYP2A6*4 allele had a lower potential for smoking dependence than individuals with the 
CYP2A6*1 allele (Akrodou, 2015; Liu et al., 2011; Minematsu et al., 2006). Base on their genotype 
and their cigarette dependence, we have identified the genotype effect on cigarette dependence among 
the respondents. The cigarette dependence was obtained based on the assessment of the Fagerstrom 
Test for Nicotine Dependence (FTND) questionnaire (Heatherton et al., 1991). 
 
Table 3. Effect of Allele gene CYP2A6*4 on cigarette dependence 
Dependency Level 
Cigarettes 







Very low - (0) 3 (9.7) - (0) 
Low 1 (3.2) 12 (38.7) - (0) 
Medium 1 (3.2) 7 (22.6) 2 (6.45) 
High - (0) 4 (12.9) - (0) 
Very high - (0) 1 (3.2) - (0) 
 
Table 3 above describes that account 48.4% of the respondents have a very low and low 
dependency. These due to the CPY2A6*4 allele was dominating among the respondents and causing a 
decrease in cigarette dependence than individuals with CYP2A6*1 allele (Akrodou, 2015; Liu et al., 
2011; Minematsu et al., 2006). Otherwise, Table 3 shows that the cigarette dependence on medium, 
high, and very high is 45.15%. The other factor that influences smoking behavior is environmental 
factors.  All of the respondents have worked as online driver motorcycle they usually could not avoid 
smoking when the other drivers are smoke (Akrodou, 2015). 
CYP2A6 is an enzyme responsible for metabolizing 70-90% nicotine and converting it into an 
inactive form by oxidizing nicotine to nicotine ions Δ1‟(5‟)-iminium. Furthermore, nicotine iminium 
ions are converted to cotinine by the enzyme aldehyde oxidase. This metabolite, cotinine, will also be 
metabolized by CYP2A6 into several hydroxylation metabolites, namely 3-hydroxycotinine, 5-
hydroxycotinine, and nor cotinine, excreted from the body (Benowitz, L et al., 2016). Smokers with 
CYP2A6*4 tend to have to decrease in nicotine metabolism. Therefore, this condition causes high 
nicotine levels in the blood, increasing LDL-C levels by stimulating the sympathetic adrenal 
system and increasing catecholamine secretion. The impact is expanding lipolysis of adipose 
tissue fat and increasing free fatty acids. In the liver, free fatty acids esterify as triacylglycerols 
and esters cholesterol. They are secreted into the bloodstream as VLDL and will convert into 
LDL, which circulates in the blood (Devaranavadgi et al., 2012). To evaluate the CYP2A6*4 allele 
on LDL-C levels among smokers, we used the odds ratio value as shown in Table 4. 
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Table 4. The CYP2A6*4 allele gene effect on LDL-C levels 
 
Allele 

















No CYP2A6*4 allele present 1 (3.2) 1 (3.2) 2 (6.5) 
Sum n(%) 19 (61.3) 12 (38.7) 31 (100)  
*P-Value >0,05 showed that the data were not significantly different between groups 
  P-Value is calculated using Mantel-Haenszel Common Odds Ratio Estimate (95% CI) 
 
In Table 4 show that 58.1% of respondents with the CYP2A6*4 allele have LDL-C levels ≥ of 
130 mg/dL. Furthermore, the calculation of the Odd Ratio shows that individuals with the CYP2A6*4 
allele have a 1.636-fold greater risk of increasing LDL-C levels than individuals without the 
CYP2A6*4 allele. Therefore, based on this odds ratio value, this result was in line with another study 
that smokers with the CYP2A6*4 allele have on decreasing the activity of the CYP2A6 enzyme, which 
causes high nicotine levels in the blood, thereby increasing LDL-C levels and reducing HDL-C levels 
(Rao and Subash, 2013). 
As described in Table 4, the P-Value obtained is > 0.05, indicates that the data is not 
significantly different between CYP2A6*4 allele present or without CYP2A6*4 allele present. This 
result can occur because the allele influence on nicotine metabolism is not only due to the CYP2A6*4 
allele. According to Mwenifumbo (2008) and Schoedel's (2004), other alleles such as the CYP2A6*7 
and CYP2A6*9 alleles can affect nicotine metabolism impact LDL-C levels. Furthermore, genotypes 
and phenotypes can be formed from the present other allele, namely normal metabolizers 
(CYP2A6*1/*1); intermediate metabolizer (CYP2A6*1/*7; CYP2A6*1/*9); slow metabolizer 
(CYP2A6*1/*4; CYP2A6*1/*7/*4; CYP2A6*1/*9/*4; CYP2A6*7/*7; CYP2A6*9/*9); and poor 
metabolizers (CYP2A6*4/*4; CYP2A6*4/*7; CYP2A6*4/*9) (Bajaj, 2012; Messner and Bernhard, 
2014; Mwenifumbo et al., 2008; Mwenifumbo and Tyndale, 2007; Nakajima et al., 2006; Schoedel et 
al., 2004).  
 Some other factors are influencing the LDL-C levels, namely smoking behavior (duration of 
smoking, cigarettes per day, and types of cigarettes used) and environmental factors (socioeconomic, 
lifestyle, level of education, and culture) (Akrodou, 2015; Minarti et al., 2014; Singh et al.,2016). 
According to the characteristic data shown in Table 1, related to the average number of cigarettes per 
day (13.5±4.4 sticks) and smoking duration (23.2±4.8 years) of the respondents, all of the respondents 
are associated as addictive smokers affecting the increase in LDL-C levels. So, it is in line with 
another study that the chronic effect of smoking behavior would arise when individuals consume more 
than 20 cigarettes per day and 25 years minimum smoking duration (Patramurti and Fenty, 2020). 
The increasing LDL-C levels in the blood could impact a high accumulation of LDL-C on the 
artery walls. Furthermore, it causes atherosclerosis in smokers, especially in individuals with the 
CYP2A6*4 allele makes them at greater risk of getting cardiovascular disease (Rao and Subash, 2013). 
Some others risk factors can affect cardiovascular disease, including BMI, waist circumference, blood 
pressure, age, and ethnicity. Based on data in Table 1, the BMI (25.1±4.8), waist circumference 
(89.5±11.3 cm), systolic blood pressure (128.4±24.1 mmHg), and diastolic blood pressure (82.6±9.4 
mmHg), among the respondents, have a higher risk. It indicated that respondents participating in this 
study were at a higher risk of cardiovascular disease (Murtiyaningsih, 2017; World Health 
Organization, 2017). Therefore, prevention of the incidence of cardiovascular disease needs to be done 
as early as possible, especially by controlling modifiable risk factors for cardiovascular disease, 
including smoking behavior, blood pressure, BMI, and lipid profile (World Health Organization, 
2017). 
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According to (World Health Organization, 2014), the cardiovascular disease caused 37% of 
mortality in Indonesia. Smoking behavior is the main factor for getting cardiovascular disease. 
Indonesia is ranking as the 3rd largest cigarette market in the world; indicating that the smoking 
cessation program does not effectively reduce smoking rates in Indonesia (Kemenkes RI, 2018). The 
current study shows high frequency of these inactive alleles among the Javanese Indonesian 
population. The effect of present inactive allele gene CYP2A6*4 causing a decrease in cigarette 
dependence than individuals with CYP2A6*1 allele. Based on our results, it will provide the necessary 
drive for tobacco control efforts of all related parties, especially the Indonesian Government. They 
must be all together engaged in suppressing smoking rates through collaboration and effective 
strategies towards a tobacco-free. Thereby the incidence rate of cardiovascular disease in Indonesia 
will be decreased. 
As state in The Regulations Guidelines Number 188/Menkes/Pb/I/2011 and Number 7 (2011), 
The Indonesian Government has issued regulations about implementing No-Smoking Areas to prevent 
passive smoking exposure to cigarette smoke. In addition, Daerah Istimewa Yogyakarta (DIY) 
Province is one of the provinces that has implemented a no-smoking area through DIY Government 
Regulation Number 42 (2009). Furthermore, the DIY Government has implemented promotive and 
preventive efforts related to the impact of smoking behavior for active smokers and passive smokers. 
The regional program and project initiatives in tobacco control, together with various levels of society, 
have been crucial areas of collaboration and cooperation that addressed the health risks associated with 
tobacco consumption in DIY. 
 
Study Limitations 
The sample size is part of the limitation of the current study.  In addition, this study only 
identifying the CYP2A6*1 and CYP2A6*4 alleles. Therefore, it was necessary required to identify 
other alleles that affect LDL-C levels. 
 
CONCLUSION 
Based on our study, we found the CYP2A6*1 and CYP2A6*4 allele genes among Javanese 
Indonesian smokers with their respective frequencies of 93.55%. Furthermore, the CYP2A6*4 allele 
gene did not impact LDL-C levels, with the Odd Ratio value was 1.636 (P-Value = 0,737). 
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